Validation Rules for Regulatory Transactions Submitted in the electronic Common Technical Document (eCTD) FormatPublished on December 4, 2022
Author: Bhavesh Patel, C. Chem.
Late last year, Health Canada announced the revised validation rules for regulatory transactions in the electronic Common Technical Document (“eCTD”) format.
These revised validation rules can be found at the reference link below to provide further information to stakeholders to assist them in the preparation of regulatory transactions in eCTD format. The revised rules build on the information provided in the Guidance Document: Preparation of Drug Regulatory Activities in Electronic Common Technical Document (eCTD) Format as well as specifications for the regional administrative module (Module1) of the eCTD standard defined in Guidance for Industry: Creation of the Canadian Module 1 Backbone (eCTD) and the International Conference on Harmonisation (ICH) Electronic Common Technical Document Specification (Version 3.2.2).
Since June 2016, Health Canada has been providing the Validation Reports only for regulatory transactions that failed validation. Sponsors are expected to validate their eCTD regulatory transactions and correct any warning(s) or error(s) before sending submission to Health Canada.
Although the profile may be updated without further notice, as of February 1st, 2018, Health Canada is validating regulatory transactions in eCTD format using version CA eCTD - Profile 4.3
Thank you for reading Regulated Affairs, the CAPRA Blog. CAPRA is a non-profit organization dedicated to providing professional development opportunities in Regulatory Affairs. Feel free to share our blog posts and join us on social media.
Pragmatic Clinical Trials: Testing Treatments in the Real-World
What is a Pragmatic Clinical Trial? Clinical trials can be designed to be either pragmatic or explanatory. Explanatory trials are designed to find out whether a treatment...
The FDA Announces Proposed Rule: Nonprescription Drug Product with an Additional Condition for Nonprescription Use – June 28, 2022
The FDA is announcing the availability of the proposed rule Nonprescription Drug Product with an Additional Condition for Nonprescription Use (Docket No. FDA-2021-N-0862)....